Search

Your search keyword '"Gerrit Stoter"' showing total 70 results

Search Constraints

Start Over You searched for: Author "Gerrit Stoter" Remove constraint Author: "Gerrit Stoter" Topic medicine.disease Remove constraint Topic: medicine.disease
70 results on '"Gerrit Stoter"'

Search Results

1. Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-α: Course and relationship with psychiatric status

2. Molecular profiling of platinum resistant ovarian cancer

Catalog

Books, media, physical & digital resources

3. Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1

4. IL-12: a promising adjuvant for cancer vaccination

5. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy

6. Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens

7. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer

8. Intrapleural administration of tumour necrosis factor-alpha (TNFα) in patients with mesothelioma: cytokine patterns and acute-phase protein response

9. Tunnelled central venous catheters yield a low incidence of septicaemia in interleukin-2-treated patients

10. The correlation of CA15.3 and TPS with tumor course in patients with metastatic breast cancer

11. The role of adoptive immunotherapy in solid cancers

12. High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer

13. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFNα and autologous IL-2-activated lymphocytes)

14. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

15. Docetaxel (Taxotere): Single agent activity, development of combination treatment and reducing side-effects

16. Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874

17. Paraneoplastic ophtalmoplegia and subacute motor axonal neuropaty associated with anti-GQ1b antibodies in a patient with malignant melanoma

18. Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication

19. Prognostic Factors in Metastatic Non-Seminomatous Germ Cell Tumours: An Interim Analysis of the EORTC GU-Group Experience

20. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study

21. Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery

22. Combination therapy of ACNU and ifosfamide in tumor bearing mice with M2661 breast cancer, B16 malignant melanoma or C38 colon cancer

23. Carcinoma of unknown primary: Identification of a treatable subset?

24. Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects

25. Analgesic adherence measurement in cancer patients: Comparison between electronic monitoring and diary

26. Late-onset retinoblastoma in a well-functioning fellow eye

27. EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors

28. Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and arginine in melanoma patients

29. What is the role of dose-dense therapy?

30. Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy

31. Oral piritrexim, an effective treatment for metastatic urothelial cancer

32. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours

33. Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer

34. Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFNα) in metastatic melanoma

35. Bleomycin and scuba diving: where is the harm?

36. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel

37. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group

38. Cisplatin - DNA adducts and protein-bound platinum in blood of testicular cancer patients

39. In vivo model systems in P-glycoprotein-mediated multidrug resistance

40. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group

41. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer

42. Surveillance versus adjuvant chemotherapy in stage I non-seminomatous testicular cancer: a decision analysis

43. Multidrug resistance-associated protein (MRP) in haematological malignancies

44. Peripheral neurotoxicity induced by docetaxel

45. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia

46. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody

47. Combination Immunotherapy with Interleukin-2 (IL-2), Alpha-Interferon (αIFN), and Autologous IL-2-Activated Lymphocytes (LAK) in Metastatic Renal Cell Cancer

48. High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia

49. Predictors of Residual Mass Histology Following Chemotherapy for Metastatic Nonseminomatous GCT: Univariate and Multivariate Meta-Analysis

50. Repetitive weekly cycles of 4-day continuous infusion of recombinant interleukin-2: a phase I study